Therini Bio develops fibrin-targeting immunotherapies to address chronic neuroinflammation and neuronal damage caused by vascular dysfunction in diseases such as Alzheimer’s and Diabetic Macular Edema. Their clinical-stage pipeline focuses on selectively eliminating toxic fibrin deposits that trigger inflammatory cascades, aiming to improve outcomes for patients with severe neurological and retinal conditions.
Funding
$62.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic neuroinflammation and neuronal damage in diseases like Alzheimer’s and Diabetic Macular Edema are often driven by vascular dysfunction. Toxic fibrin deposits trigger inflammatory cascades, exacerbating these conditions.
Solution
Therini Bio is developing fibrin-targeting immunotherapies designed to address neuroinflammation and neuronal damage resulting from vascular dysfunction. Their clinical-stage pipeline focuses on selectively eliminating toxic fibrin deposits, which are known to initiate inflammatory cascades. By targeting and removing these deposits, the company aims to interrupt the cycle of inflammation and improve outcomes for patients suffering from severe neurological and retinal diseases. This approach seeks to halt the progression of neurodegenerative conditions by addressing the underlying vascular component.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Alzheimer’s Disease and retinal conditions like Diabetic Macular Edema, as well as the healthcare providers who treat them.
Features
- Fibrin-targeted immunotherapy approach
- Selective elimination of toxic fibrin deposits
- Clinical-stage pipeline focused on neurodegenerative and retinal diseases
- Designed to interrupt inflammatory cascades triggered by vascular injury